Anti-tuberculosis activity of Rivaroxabane in silico and in vitro
https://doi.org/10.29235/1561-8323-2023-67-3-207-213
Abstract
The activity of Rivaroxoban of oxazolidinone series against Mycobacterium terrae was investigated in silico and in vitro. In silico studies have shown a high binding affinity of Rivaroxaban to β-ketoacyl[ACP]synthase I that plays a key role in the biosynthesis of mycolic acids, being the components of the mycobacterial cell wall. In the molecular docking study, two main binding sites of Rivaroxaban with protein were predicted and evaluated: the minimum binding energies were found for the both sites with the values of –10.26 kcal/mol and –8.99 kcal/mol. A solution of Rivaroxaban (200 μg/ml) has been shown to inhibit the growth of a Mycobacterium terrae culture. The data obtained open up the prospect of developing new effective anti-tuberculosis drugs of oxazolidinone series.
About the Authors
T. T. Lakhvich
Belarusian State Medical University
Belarus
Belarus
Lakhvich Todar T. – Ph. D. (Chemistry), Associate Professor
83, Dzerzhynski Ave., 220083, Minsk, Republic of Belarus
V. M. Ryneiskaya
Belarusian State Medical University
Belarus
Belarus
Ryneiskaya Volha M. – Ph. D. (Medicine), Associate Professor, Head of the Department
83, Dzerzhynski Ave., 220083, Minsk, Republic of Belarus
N. S. Golyak
Belarusian State Medical University
Belarus
Belarus
Golyak Natalia S. – Ph. D. (Pharmacy), Associate Professor, Head of the Department
83, Dzerzhynski Ave., 220083, Minsk, Republic of Belarus
N. K. Yurkshtovich
State company “Academpharm”
Belarus
Belarus
Yurkshtovich Nikolay K. – Ph. D. (Chemistry), Deputy Director
5/3, Kuprevich Str., 220084, Minsk, Republic of Belarus
K. E. Nasennikava
State company “Academpharm”
Belarus
Belarus
Nasennikava Katsiaryna E. – Head of the Laboratory
5/3, Kuprevich Str., 220084, Minsk, Republic of Belarus
F. A. Lakhvich
Institute of Bioorganic Chemistry of the National Academy of Sciences of Belarus
Belarus
Belarus
Lakhvich Fiodar A. – Academician, D. Sc. (Chemistry), Professor, Chief Researcher
5/2, Kuprevich Str., 220084, Minsk, Republic of Belarus
References
1. Leimane V., Riekstina V., Holtz T., Zarovska E., Skripconoka V., Thorpe L. E., Laserson K. F., Wells C. D. Clinical outcome of individualized treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet, 2005, vol. 365, no. 9456, pp 318–326. https://doi.org/10.1016/s0140-6736(05)17786-1
2. Global tuberculosis report 1997–2021. World Health Organization. Available at: https://www.who.int/tb/publications/global_report/en/ (accessed 01 June 2022).
3. Li K., Schurig-Briccio L. A., Feng X., Upadhyay A., Pujari V., Lechartier B., Fontes F. L. [et al.]. Multitarget Drug Discovery for Tuberculosis and Other Infectious Diseases. Journal of Medicinal Chemistry, 2014, vol. 57, no. 7, pp. 3126−3139. https://doi.org/10.1021/jm500131shttps://doi.org/10.3947/ic.2019.51.2.142
4. Lakhvich T. T., Zushchik P. Yu., Lakhvich A. T. Rational design of the model of acyclic analogues of hydroxyisonipecotic acids. BGMU v avangarde meditsinskoi nauki i praktiki [Advances in medicine and medical sciences: collection of Belarusian state medical university]. Minsk, 2019, vol. 9, pp. 389–399 (in Russian).
5. Lakhvich T. T., Borava M. I.., Ryneiskaya V. M. In silico SAR studies of oxazolidinones as potential anti-tuberculosis drugs. BGMU v avangarde meditsinskoi nauki i praktiki [Advances in medicine and medical sciences: collection of Belarusian state medical university]. Minsk, 2019, iss. 12, vol. 2, pp. 200–205 (in Russian).
6. Ha H., Kim K. H., Park J. H., Lee J. K., Heo E. Y., Kim J. S., Kim D. K., Choi I. S., Chung H. S., Lim H. J. Thromboembolism in Mycobacterium tuberculosis Infection: Analysis and Literature Review. Infection and Chemotherapy, 2019, vol. 51, no. 2, pp. 142–149. https://doi.org/10.3947/ic.2019.51.2.142
7. Luckner S. R., Machutta C. A., Tonge P. J., Kisker C. Crystal structures of Mycobacterium tuberculosis KasA show mode of action within cell wall biosynthesis and its inhibition by thiolactomycin. Structure, 2009, vol. 17, no. 7. pp. 1004–1013. https://doi.org/10.1016/j.str.2009.04.012
8. Morris G. M., H uey R ., L indstrom W., Sanner M. F., Belew R. K., Goodsell D. S., Olson A. J. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. Journal of Computational Chemistry, 2009, vol. 30, no. 16, pp. 2785–2791. https://doi.org/10.1002/jcc.21256
9. Griffiths P. A., Babb J. R., Fraise A. P. Mycobacterium terrae: a potential surrogate for Mycobacterium tuberculosis in a standard disinfectant test. Journal of Hospital Infection, 1998, vol. 38, no. 3, pp 183–192. https://doi.org/10.1016/s0195-6701(98)90273-0
10. Assessment report Xarelto Rivaroxaban. European Medicines Agency. Available at: https://www.ema.europa.eu/en/documents/variation-report/xarelto-h-c-944-x-0010-epar-assessment-report-extension_en.pdf (accessed 01 June 2022).
Review
Views: 282
Email this article 